Thomson Reuters released a report that provides a view of the challenges facing companies entering the United States biosimilar drug market.
The IP & Science business of Thomson Reuters released a life sciences report, “An Outlook on U.S. Biosimilar Competition,” which provides a view of the challenges facing companies entering the United States biosimilar drug market and key players predicted to break into this developing pharmaceutical space.
While the US continues to take steps toward entering the global biosimilar market, it lags behind other nations in this space, the report says. The report compares US and EU regulations to underscore the significant differences between these regions and explore ways the US can compete more effectively, in addition to reviewing emerging regulatory developments in India and China. It also identifies potential leaders of the US market, including Amgen, Hospira, and Sandoz, among the top pharmaceutical companies with the most potential to dominate the early stages of biosimilar medications entering the US.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.